Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 17/20 | 0.57 |
| ▸ | CDK4 | P11802 | 6/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.57 |
| ▸ | CCND1 | P24385 | 6/20 | 0.57 |
| ▸ | CDK2 | P24941 | 6/20 | 0.57 |
| ▸ | CCND3 | P30281 | 6/20 | 0.57 |
| ▸ | CDK1 | P06493 | 5/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586434 | 1.00 | TTK (1.00) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL585701 | 0.85 | TTK (0.73) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL585700 | 0.85 | TTK (0.73) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL3719616 | 0.81 | TTK (0.68) | TTKCHEK1CDK4AURKBKDR | |
| SCHEMBL3719619 | 0.81 | TTK (0.68) | TTKCHEK1CDK4AURKBKDR | |
| SCHEMBL6533458 | 0.81 | TTK (0.66) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL6533456 | 0.81 | TTK (0.66) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL12795390 | 0.81 | TTK (0.66) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL29921084 | 0.78 | TTK (0.64) | TTKCHEK1CDK4CCNA2CCND1 | |
| SCHEMBL586320 | 0.78 | TTK (0.64) | TTKCHEK1CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| US-9139563-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2015-09-22 | — | — | US | disclosed |
| US-8999968-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2015-04-07 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| EP-2417127-B1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2014-02-26 | — | — | EP | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| CN-101970426-A | Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIV HEALTH NETWORK | 2011-02-09 | — | — | CN | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885CHEK1 109/4885CDK4 177/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | TTK 421/4885CHEK1 97/4885CDK4 359/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | TTK 53/4885CHEK1 88/4885CDK4 167/4885 |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885CHEK1 109/4885CDK4 177/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885CHEK1 109/4885CDK4 177/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885CHEK1 109/4885CDK4 177/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | TTK 93/4885CHEK1 109/4885CDK4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.